Patents by Inventor Dirk Behnke

Dirk Behnke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11458138
    Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 4, 2022
    Assignee: Novartis AG
    Inventors: Dirk Behnke, Frada Berenshteyn, Xueshi Hao, Timothy Hoffman, Qihui Jin, Arnaud Lacoste, Cameron Lee, Jun Liu, Yahu Liu, Juergen Klaus Maibaum, Tingting Mo, Jianfeng Pan, Xin Qu, Jan Tchorz, Yun Feng Xie, Shanshan Yan, Yefen Zou
  • Publication number: 20220246388
    Abstract: A multiple particle beam microscope and an associated method set a desired focal plane with an optical resolution and set a telecentric irradiation with the plurality of the primary beams. A method determines an optimal setting plane, into which an object surface is brought. Further, a system provides an improved resolution and telecentric irradiation for a large number of primary beams. Targeted selection and targeted individual influencing of individual primary beams and/or a mechanism means for influencing the plurality of primary beams in collective fashion can be implemented.
    Type: Application
    Filed: January 24, 2022
    Publication date: August 4, 2022
    Inventors: Nicole Rauwolf, Nico Kaemmer, Michael Behnke, Ingo Mueller, Dirk Zeidler, Arne Thoma, Christof Riedesel, Gunther Scheunert
  • Publication number: 20180344738
    Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.
    Type: Application
    Filed: April 26, 2018
    Publication date: December 6, 2018
    Inventors: Dirk BEHNKE, Frada BERENSHTEYN, Xueshi HAO, Timothy HOFFMAN, Qihui JIN, Arnaud LACOSTE, Cameron LEE, Jun LIU, Yahu LIU, Juergen Klaus MAIBAUM, Tingting MO, Jianfeng PAN, Xin QU, Jan TCHORZ, Yun Feng XIE, Shanshan YAN, Yefen ZOU
  • Publication number: 20170305903
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 26, 2017
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Patent number: 9650377
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Dirk Behnke, David Carcache, Peter Ertl, Manuel Koller, David Orain
  • Publication number: 20160159795
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Patent number: 9284331
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: March 15, 2016
    Assignee: Novartis AG
    Inventors: Dirk Behnke, David Carcache, Peter Ertl, Manuel Koller, David Orain
  • Publication number: 20140357625
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: August 19, 2014
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Patent number: 8853203
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: October 7, 2014
    Assignee: Novartis AG
    Inventors: Dirk Behnke, David Carcache, Peter Ertl, Manuel Koller, David Orain
  • Patent number: 8742106
    Abstract: The invention relates to compound of the formula (I?) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 3, 2014
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Murali Chebrolu, Simona Cotesta, Samuel Hintermann, Arndt Meyer, Chetan Pandit
  • Publication number: 20140057902
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Dirk BEHNKE, David CARCACHE, Peter ERTL, Manuel KOLLER, David ORAIN
  • Publication number: 20130281463
    Abstract: The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: October 25, 2011
    Publication date: October 24, 2013
    Applicant: NOVARTIS AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Simona Cotesta, Samuel Hintermann, Silvio Ofner, Chetan Pandit, Bernard Lucien Roy
  • Patent number: 8530648
    Abstract: The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: September 10, 2013
    Assignee: Novartis AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Simona Cotesta, Jürgen Hans-Hermann Hinrichs, Silvio Ofner, Chetan Pandit, Jürgen Wagner
  • Publication number: 20120264748
    Abstract: The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 18, 2012
    Applicant: NOVARTIS AG
    Inventors: Sangamesh Badiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Simona Cotesta, Jürgen Hans-Hermann Hinrichs, Silvio Ofner, Chetan Pandit, Jürgen Wagner
  • Publication number: 20120258973
    Abstract: The invention relates to compound of the formula (I?) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 11, 2012
    Applicant: NOVARTIS AG
    Inventors: Sangamesh Babiger, Dirk Behnke, Claudia Betschart, Vinod Chaudhari, Murali Chebrolu, Simona Cotesta, Samuel Hintermann, Arndt Meyer, Chetan Pandit
  • Publication number: 20120165331
    Abstract: The invention relates to compounds of the formula I A-D-C(R1)2—B??(I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 19, 2011
    Publication date: June 28, 2012
    Inventors: Sangamesh BADIGER, Dirk BEHNKE, Claudia BETSCHART, Vinod CHAUDHARI, Simona COTESTA, Samuel HINTERMANN, Andreas LERCHNER, Fatma LIMAM, Silvio OFNER, Chetan PANDIT, Jürgen WAGNER
  • Publication number: 20120115859
    Abstract: The application relates to novel substituted piperidines of the general formula (II) in which R1?, R2?, R2?, R4?, X, Z, m and n have the meanings defined in the description, to a process for the preparation thereof and to the use of these compounds as medicines, especially as renin inhibitors.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 10, 2012
    Inventors: Peter HEROLD, Robert Mah, Vincenzo Tschinke, Nathalie Jotterand, Dirk Behnke, Aleksandar Stojanovic, Stefan Stutz, Michael Quirmbach, Stjepan Jelakovic
  • Publication number: 20120101110
    Abstract: The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: October 18, 2011
    Publication date: April 26, 2012
    Inventors: Sangamesh BADIGER, Dirk BEHNKE, Claudia BETSCHART, Simona COTESTA, Samuel HINTERMANN, Silvio OFNER, Chetan PANDIT, Bernard Lucien ROY
  • Patent number: 8071651
    Abstract: Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl-C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: December 6, 2011
    Assignee: Novartis AG
    Inventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Stefan Stutz, Aleksandar Stojanovic, Christiane Marti, Dirk Behnke, Stjepan Jelakovic
  • Patent number: 8022068
    Abstract: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: September 20, 2011
    Assignee: Novartis AG
    Inventors: Dirk Behnke, Peter Herold, Stjepan Jelakovic, Robert Mah, Vincenzo Tschinke